Banxia Xiexin Decoction reshapes tryptophan metabolism to inhibit progression of colon cancer.
10.19540/j.cnki.cjcmm.20241014.702
- Author:
Yi-Fang JIANG
1
;
Yu-Qing HUANG
1
;
Heng-Zhou LAI
1
;
Xue-Ke LI
1
;
Liu-Yi LONG
2
;
Feng-Ming YOU
3
;
Qi-Xuan KUANG
1
Author Information
1. Traditional Chinese Medicine Regulating Metabolic Diseases Key Laboratory of Sichuan Province,Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China.
2. Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China.
3. Traditional Chinese Medicine Regulating Metabolic Diseases Key Laboratory of Sichuan Province,Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China Cancer Institute, Chengdu University of Traditional Chinese Medicine Chengdu 610072, China.
- Publication Type:Journal Article
- Keywords:
Banxia Xiexin Decoction;
CD8~+ T cells;
MYC/SLC7A5 pathway;
colon cancer;
tryptophan metabolism
- MeSH:
Animals;
Tryptophan/metabolism*;
Colonic Neoplasms/pathology*;
Mice;
Drugs, Chinese Herbal/administration & dosage*;
Mice, Inbred BALB C;
Humans;
Cell Line, Tumor;
Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism*;
Female;
Disease Progression;
Cell Proliferation/drug effects*;
Proto-Oncogene Mas;
Male
- From:
China Journal of Chinese Materia Medica
2025;50(5):1310-1320
- CountryChina
- Language:Chinese
-
Abstract:
This study explores the effect and mechanism of Banxia Xiexin Decoction(BXD) in inhibiting colon cancer progression by reshaping tryptophan metabolism. Balb/c mice were assigned into control, model, low-dose BXD(BXD-L), and high-dose BXD(BXD-H) groups. Except the control group, the other groups were subcutaneously injected with CT26-Luc cells for the modeling of colon cancer, which was followed by the intervention with BXD. Small animal live imaging was employed to monitor tumor growth, and the tumor volume and weight were measured. Hematoxylin-eosin(HE) staining was used to observe the pathological changes in mouse tumors. Immunohistochemistry was used to detect Ki67 expression in tumors. Immunofluorescence and flow cytometry were used to detect the infiltration and number changes of CD3~+/CD8~+ T cells in the tumor tissue. Enzyme-linked immunosorbent assay(ELISA) was employed to measure the levels of interferon-gamma(IFN-γ) and interleukin-2(IL-2) in tumors. Targeted metabolomics was employed to measure the level of tryptophan(Trp) in the serum, and the Trp content in the tumor tissue was measured. Western blot and RT-qPCR were employed to determine the protein and mRNA levels, respectively, of indoleamine 2,3-dioxygenase 1(IDO1), MYC proto-oncogene, and solute carrier family 7 member 5(SLC7A5) in the tumor tissue. Additionally, a co-culture model with CT26 cells and CD8~+ T cells was established in vitro and treated with the BXD-containing serum. The cell counting kit-8(CCK-8) assay was used to examine the viability of CT26 cells. The content of Trp in CT26 cells and CD8~+ T cells, as well as the secretion of IFN-γ and IL-2 by CD8~+ T cells, was measured. RT-qPCR was used to determine the mRNA levels of MYC and SLC7A5 in CT26 cells. The results showed that BXD significantly inhibited the tumor growth, reduced the tumor weight, and decreased the tumor volume in the model mice. In addition, the model mice showed sparse arrangement of tumor cells, varying degrees of patchy necrosis, and downregulated expression of Ki67 in the tumor tissue. BXD elevated the levels of IFN-γ and IL-2 in the tumor tissue, while upregulating the ratio of CD3~+/CD8~+ T cells and lowering the levels of Trp, IDO1, MYC, and SLC7A5. The co-culture experiment showed that BXD-containing serum reduced Trp uptake by CT26 cells, increased Trp content in CD8~+T cells, enhanced IL-2 and IFN-γ secretion of CD8~+T cells, and down-regulated the mRNA levels of MYC and SLC7A5 in CT26 cells. In summary, BXD can inhibit the MYC/SLC7A5 pathway to reshape Trp metabolism and adjust Trp uptake by CD8~+ T cells to enhance the cytotoxicity, thereby inhibiting the development of colon cancer.
